NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel…
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its…
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA…
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in…
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…
Significant pipeline advancementsStrategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10BnKey senior management hires LONDON, UK /…
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASESSTRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING…
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company…
Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's DiseaseNovel therapeutic with Fast Track and Orphan DesignationLONDON, UK /…